Answers are grounded in this paper and cite their sources.
From 1-(4-((E)-(substituted phenylimino)methyl)-3-(4-fluorophenyl)-1H-pyrazol-1-yl)-2-phenylethanone (3a-n), a series of compounds 3-chloro-4-(3-(4-fluorophenyl)-1-(2-phenylacetyl)-1H-pyrazol-4-yl)-1 (substituted phenyl)azetidin-2-one (4a-n). The condensation reaction between 3-(4-fluorophenyl)-1-(2-phenylacetyl)-1H-pyrazole-4 carbaldehyde (2) and aromatic amines in acidic environment produced the series of compounds (3a–n). Using the well-known VilsmeierHaack reagent, compound (2) was created from N'-(1-(4-fluorophenyl)ethylidene)-2-phenylacetohydrazide (1). In a well-equipped lab, the reaction conditions were established by careful observation. Spectroscopic methods and elemental analysis were used to verify the structures of the produced substances. primarily mass spectrometry, 1HNMR, 13CNMR, and FT-IR. Using a controlled standard of 19±0.28 and 17.5±0.58 against Gram positive and Gram negative bacterial strains, respectively, antimicrobial properties were investigated. While compounds 4-h and 4-n demonstrated moderate activity, compound 4-e shown encouraging antibacterial activity. The findings encouraged us to carry out more research in order to build other investigative studies. Additionally, to increase the value of NCEs that have been modified.
No takes yet. Share an insight, caveat, or question.
Vipin et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: